Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery (NCT07583134) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery
South Korea100 participantsStarted 2026-05-26
Plain-language summary
This study aims to evaluate the impact of using propranolol, a non-selective beta-blocker, on preventing myocardial injury after non-cardiac surgery (MINS) in breast cancer patients who also have hypertension or angina. Stress from surgery and anesthesia can increase sympathetic activity and inflammation, which may lead to heart stress. This pragmatic clinical trial will compare patients who are prescribed propranolol as part of their routine care with those who are not. Researchers will analyze blood samples and surgical tissues collected during normal treatment to observe changes in heart health and the tumor microenvironment.
Who can participate
Age range
20 Years – 70 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Female patients aged 20 to 70 years.
. Patients diagnosed with hypertension or angina who require medication.
. Patients diagnosed with unilateral, resectable primary breast cancer (ICD-10: C50), Stage I-III.
. ECOG performance status of 0-1.
. Patients scheduled to receive standard postoperative treatment (including adjuvant radiotherapy
. Patients who voluntarily decide to participate and sign the written informed consent form
Exclusion criteria
What they're measuring
1
Incidence of Myocardial Injury after Noncardiac Surgery (MINS)
Timeframe: From the day of surgery (Day 0) up to 30 days postoperatively
. Patients with active infectious diseases, autoimmune diseases (including specific rheumatic diseases), coagulation disorders, or cardiovascular diseases other than hypertension or angina pectoris.
. Patients with clinically significant hepatic, hematologic, or renal dysfunction, defined as any of the following:
. Patients with moderate to severe asthma or chronic obstructive pulmonary disease (COPD).
. Patients who are pregnant or breastfeeding at the time of enrollment.
. Patients with a history of malignancy within the past 5 years.
. Patients for whom data collection is considered difficult at the discretion of the investigator.
. Patients who are unable to understand or complete study questionnaires.